Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927327 · ClinicalTrials.gov registry record · NA
Clinical Evaluation Of MP26 Features in Adults
A NA study of Brain Imaging and Whole Body Imaging, sponsored by GE Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT02927327: Completed NA study of Brain Imaging and Whole Body Imaging, sponsored by GE Healthcare.
NCT02927327 is a NA study of Brain Imaging and Whole Body Imaging that has completed, run by GE Healthcare. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02927327, a NA study of Brain Imaging and Whole Body Imaging, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to collect representative clinical images (head and whole-body scans) of demonstrated diagnostic quality using the next-generation SIGNA PET/MR device equipped with investigational software components in adult population. The images and summary data from this study are intended for use in regulatory submission.
Primary Outcome
scored on a 5-pt Likert scale: 1. Unacceptable 2. Poor 3. Acceptable 4. Good 5. Excellent
Conditions Studied
Interventions
- DEVICE Zero Echo Time (ZTE) scan for head attenuation
- DEVICE Q.Static (Q. MRAC) for respiratory motion correction
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-09-20 |
| Phase | NA |
What the finished NCT02927327 record still lists
NCT02927327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Brain Imaging appearing as the primary indexed condition, and to 2 interventions - of which Zero Echo Time (ZTE) scan for head attenuation is the first listed.
NCT02927327 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02927327 about?
NCT02927327 is a clinical study titled "Clinical Evaluation Of MP26 Features in Adults". The purpose of the study is to collect representative clinical images (head and whole-body scans) of demonstrated diagnostic quality using the next-generation SIGNA PET/MR device equipped with investigational software components in adult population. The images and summary data from this study are in...
What is the current status of trial NCT02927327?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2016-11. Estimated completion is 2017-09-20.
What conditions does trial NCT02927327 study?
This clinical trial studies the following conditions: Brain Imaging, Whole Body Imaging.
What interventions are being tested in trial NCT02927327?
The interventions under investigation include: Zero Echo Time (ZTE) scan for head attenuation (DEVICE), Q.Static (Q. MRAC) for respiratory motion correction (DEVICE).
Who is sponsoring clinical trial NCT02927327?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02927327 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Imaging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02927327's enrollment target sits among peer trials
61 1164th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia